Biocompatibility Testing Under ISO 10993: How to Build Your Test Matrix by Contact Type and Duration

Why Your Biocompatibility Strategy Can Make or Break Your Submission Timeline

Biocompatibility testing is one of the most misunderstood — and most commonly under-planned — components of a medical device submission. Sponsors frequently either over-test (burning time and budget on unnecessary assays) or under-test (triggering FDA requests for additional data mid-review). Neither outcome is acceptable when you are racing toward a 510(k) clearance or PMA approval.

The foundation of a defensible biocompatibility program is ISO 10993-1:2018, Biological Evaluation of Medical Devices — Part 1: Evaluation and Testing Within a Risk Management Process. But the standard does not stand alone. FDA's 2020 guidance document, Use of International Standard ISO 10993-1 Biological Evaluation of Medical Devices — Part 1, significantly expanded FDA's expectations and introduced concepts that are not always obvious from reading the ISO standard itself. If your team is building a test matrix without that guidance open on the table, you are working from an incomplete picture.

Step One: Classify Your Device by Contact Nature and Duration

Before you run a single test, you need to answer two foundational questions: What does your device contact? and For how long? ISO 10993-1 and FDA's guidance use these two axes to drive every subsequent decision.

Contact Nature Categories

• Surface-contacting devices: Intact skin, mucosal membranes, or breached or compromised surfaces
• Externally communicating devices: Blood path indirect, tissue/bone/dentin communicating, or circulating blood
• Implant devices: Tissue/bone or blood

The distinction between 'mucosal membrane' and 'breached surface' matters enormously. A wound dressing contacting intact skin carries a very different biological risk profile than one contacting a chronic wound. Misclassifying contact nature at the outset can result in an incomplete test matrix that FDA will flag during substantive review.

Contact Duration Categories

• Limited: Single or multiple exposure, cumulative duration of 24 hours or less
• Prolonged: Cumulative exposure between 24 hours and 30 days
• Permanent: Cumulative exposure exceeding 30 days

Pay close attention to the word cumulative. FDA's 2020 guidance explicitly states that cumulative contact duration must account for repeated use over a device's lifetime. A single-use catheter used once for 90 minutes is limited contact. The same catheter used daily for six weeks is not — it crosses into prolonged, and your test matrix must reflect that clinical reality.

Building the Test Matrix: What ISO 10993-1 Table 1 Actually Tells You

Table 1 of ISO 10993-1:2018 is the starting point, not the finish line. It maps contact categories to a set of biological effect endpoints that must be addressed — not necessarily tested in a laboratory. FDA's guidance reinforces this: the biological evaluation is a risk management exercise, and existing data (literature, material characterization, predicate device data) can satisfy endpoints without generating new in vitro or in vivo data.

The core endpoints you must address include:

• Cytotoxicity
• Sensitization
• Irritation or intracutaneous reactivity
• Systemic toxicity (acute)
• Subacute and subchronic toxicity (for prolonged/permanent contact)
• Genotoxicity
• Implantation (for implant devices)
• Hemocompatibility (for blood-contacting devices)
• Chronic toxicity and carcinogenicity (for permanent contact)
• Reproductive and developmental toxicity (risk-based assessment required)

For permanent implants or devices with circulating blood contact, degradation testing per ISO 10993-9, -13, -14, and -15 is also expected. FDA's guidance adds a requirement for a chemical characterization under ISO 10993-18 before deciding whether toxicological risk assessment (per ISO 10993-17) can replace animal testing. This is not optional — it is now a standard FDA expectation across nearly all device categories.

Common Planning Mistakes That Trigger FDA Deficiencies

Based on experience reviewing FDA deficiency letters and working through biocompatibility responses, the following gaps appear repeatedly:

• Failing to conduct chemical characterization before selecting the test battery, leaving no toxicological basis for skipping endpoints
• Using extraction conditions that do not reflect actual clinical use (wrong solvent polarity, temperature, or surface-area-to-volume ratio per ISO 10993-12)
• Omitting a written biological evaluation plan (BEP) and biological evaluation report (BER) — FDA expects both as part of the submission package
• Applying a 'worst-case' predicate argument without documenting material equivalence at the formulation level
• Not updating the biocompatibility evaluation when a manufacturing process or material supplier changes post-clearance

Integrating Biocompatibility Into Your Design History File Early

Under 21 CFR Part 820 (and the updated Quality System Regulation aligned with ISO 13485), biocompatibility is a design control requirement, not a pre-submission afterthought. The BEP should be initiated during design inputs and updated as materials are finalized. Waiting until the device is locked to commission testing adds months to your timeline and limits your ability to make material changes without regulatory consequence.

If you are preparing a 510(k), your biocompatibility summary must demonstrate that all applicable endpoints in Table 1 have been addressed, with clear rationale for any endpoint that is waived. If you are pursuing a PMA, expect deeper scrutiny, including FDA review of your raw test reports and extraction methodologies.

Work With an Expert Before You Commission a Single Test

The cost of running the wrong test — or running the right test under the wrong conditions — is not just the lab invoice. It is the three to six months of submission delay while you generate replacement data. A well-constructed biological evaluation plan, built before you engage a testing laboratory, is the single highest-value investment you can make in your biocompatibility program.

At ADB Consulting and CRO Inc., Andre Butler and the team help medical device companies design biocompatibility strategies that are scientifically defensible, FDA-aligned, and efficient. Whether you are starting fresh with a novel device or resolving a deficiency letter on an existing submission, we can help you build a clear path forward.

Book a free discovery call at adbccro.com and let us review your current biocompatibility plan — before FDA does.